Introduction
It is widely accepted in various scientific communities that indoor microbiological contamination presents unacceptable conditions for the preservation of human health, and that removal and prevention of microbial contamination is necessary and prudent. (Pope, Patterson et al. 1993; EPA 2001; ACOEM 2002; Redd 2002 ) Additionally, it is well established that fungal and bacterial bioaerosols cause infections and hypersensitivity diseases and that bioaerosols in the indoor environment can cause toxic effects (Karunasena E, Larrañaga MD et al. 2010 ) and nosocomial infections to immunocompromised individuals, it is reasonable to use indicators of environmental contamination for evaluating the need for remediation in a preventative context. The presence of fungi on indoor surfaces is often considered de facto evidence of human exposure to fungal aerosols, and the apparent absence of visible or measurable indoor growth does not ensure the absence of exposure. (Burge 2000) Fungi are designed for airborne dispersal from surface growth, and for many fungi, air movement is sufficient to produce spore aerosols. (Burge 2000) The objective of this chapter is to provide a mechanism for the indoor environmental professional to describe the health risk of the indoor environment with a single unit of measurement, providing decision makers a useful evaluation of the risk presented by the growth of microorganisms indoors. the false ceiling was not considered impeded because microbial contamination above ceiling tiles has been shown to move through pores in ceiling tiles and cause nosocomial infections in the space below the false ceilings (Arnow, Andersen et al. 1978 ) and positive pressure above the false ceilings allows the exchange of air between the space indoors and the space above the false ceilings. See the Assured HVAC report for a detailed description of pressure differentials within the Hospital.
Determination of the exposure score
The exposure score is the maximum of the tape sample and swab sample scores divided by the Exposure Pathway Score: The information necessary to determine the growth and contamination scores are identified in the Center for Indoor Air Research's Standard Operating Procedures laboratory result sheets for each sample. The laboratory sheets for each sample specify the following: 1) the presence of a fungal growth site for determination of the Growth Score (Table 1) , and 2) the laboratory defined level of contamination identified by the tape sample for determination of the Tape Sample Score (Table 2 ) and 3) the laboratory defined level of contamination identified by the swab sample for determination of the swab sample score. Note: Utilize the maximum value of the scores from Tables 1-2 when determining the Tape Sample Score. The Growth Score (Table 1) and Tape Contamination Score (Table 2) can be determined by utilizing information presented in the lab sheet for each sample and the estimated surface area of growth or contamination to calculate a value. Table 1 is utilized to determine the Growth Score. If the location is not identified as a growth site, then the growth score is zero. To determine the Growth Score, multiply the Location Multiplier (values of 1 or 2) by the Growth Multiplier (values of 0 to ≥ 4) found in Table 1 . Two Examples are provided: 1. For 35 square feet of fungal growth in a critical area, then the Growth Score is found by multiplying the Location Multiplier which is 2 for a critical area by the Growth Multiplier represented by 35 square feet of growth. a. The Location Multiplier for a critical Area is 2 and the Growth Multiplier representing 35 square feet of growth is 2.5. Therefore, the Growth Score would be 2 x 2.5 = 5. 2. For 225 square feet of growth in a non-critical area, the Growth Score is found by multiplying the Location Multiplier which is 1 for a non-critical area and the Growth Multiplier represented by 225 square feet of growth, which would be 4 + 1 (for 100 square feet of additional growth) = 5. Therefore, the Growth Score would be 5 x 1 = 5. To determine the Tape Contamination Score, multiply the Location Multiplier (values of 1 or 2) by the Tape Multiplier (values of 0 to ≥4) found in EPA 2001; NYCDHMH 2006; VUMC 2006) >0-2 ft 2 = add 0 >2-4 ft 2 = add 0.2 >4-6 ft 2 = add 0.4 >6-8 ft 2 = add 0.6 >8-10 ft 2 = add 0.8 >10-20 ft 2 = add 0 >20-30 ft 2 = add 0.25 >30-40 ft 2 = add 0.5 >40-50 ft 2 = add 0.75 >50-60 ft 2 = add 0 >60-70 ft 2 = add 0.2 >70-80 ft 2 = add 0.4 >80-90 ft 2 = add 0.6 >90-100 ft 2 = add 0.8 >100 ft 2 (Add 1 to Tape  Multiplier for  every  additional 100 ft 2 of contamination) * A critical area is defined as areas within the following healthcare function spaces: Surgery and Critical Care, Ancillary, Nursing, Diagnostic and Treatment, and Sterilizing and Supply. (ASHRAE 2003) ** A non-critical care area is defined as areas within the following healthcare function spaces: Administration and Service. (ASHRAE 2003) *** See the following references for protection levels associated with surface areas of contamination: USEPA 2001; NYCDHMH 2006; VUMC 2006) Tape Multiplier representing 35 square feet of moderate or medium contamination is 2.5. Therefore, the Tape Contamination Score is 2 x 2.5 = 5. 4. For 225 square feet of moderate or medium contamination in a non-critical area, the Tape Contamination Score is found by multiplying the Location Multiplier which is 1 for a noncritical area and the Tape Multiplier represented by 225 square feet of moderate or medium contamination, which would be 3 + 1 (for 100 square feet of additional contamination) = 4. Therefore, the Tape Contamination Score would be 4 x 1 = 4.
Determination of the growth score

Determination of Swab Sample Score (SS): accounts for swab contamination results
The laboratory sheets for each sample specify the laboratory defined level of contamination identified by the swab sample for determination of the swab sample score.
To determine the Swab Sample Score, multiply the Location Multiplier (values of 1 or 2) by the Tape Multiplier (values of 0 to ≥4) found in Table 3 . 
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Two Examples are provided: 1. For 35 square feet of Light or Medium Contamination in a critical area, then the Swab Sample Score is found by multiplying the Location Multiplier which is 2 for a critical area by the Swab Multiplier represented b y 3 5 s q u a r e f e e t o f L i g h t o r M e d i u m Contamination is 2 + 0.5 (modifier to account for 35 square feet of contamination) = 2.5. a. The Location Multiplier for a critical Area is 2 and the Swab Multiplier representing 35 square feet of light or medium contamination is 2.5. Therefore, the Swab Sample Score is 2 x 2.5 = 5. 2. For 225 square feet of growth in a non-critical area, the Swab Sample Score is found by multiplying the Location Multiplier which is 1 for a non-critical area and the Swab Multiplier represented by 225 square feet of growth, which would be 3 + 1 (for 100 square feet of additional growth) = 4. Therefore, the Swab Contamination Score would be 4 x 1 = 4.
Exposure Pathway score (EP)
The Health Risk equation was modified to include an Exposure Pathway Score that compensated for microbial contamination or growth that was likely impeded from reaching a building occupant and causing pathogenic effects. See Table 4 . Tables 6 and 7 below. Organisms were identified as opportunistic/pathogenic, allergenic, and/or toxigenic if the organism identified was identified as potentially capable of producing a toxin (e.g. aflatoxin, endotoxin, satratoxin). In cases where multiple organisms were identified on a sample, the highest toxicity/pathogenicity score was assigned to the health risk calculation. Note: Where multiple organisms are identified on the same sample, the highest Toxicity/Pathogenicity score of the identified organisms is assigned to the calculation. Table 5 . Determination of Toxicity/Pathogenicity Score
EP
TP
Calculation of health risk score
Health risk scoring interpretation
The criteria for determining the health risk ratings of de minimis, low, medium, and high risk were determined by input from the investigators, peer reviewers, and specialists. Since no guidelines or limits of exposure exist, the expert input was utilized to create estimates of risk based on professional judgment and experience in the fields of medicine, engineering, infection control nursing, industrial hygiene, public health, and medical microbiology. The risk score interpretations and defining criteria are defined as: Low Risk Range = 1-11 (rounded down) Medium: The environmental conditions present an increased risk for adverse health effects to building occupants due to environmental contamination. The indoor environment suggests that immunosuppressed or allergic patients within the hospital are not fully protected against the risk of infection and the allergenic effects due to exposure to environmental-source fungi and bacteria. (Pope, Patterson et al. 1993; Perdelli, Christina et al. 2006 ) Remediation is necessary. Containment is necessary. Persons within the remediation area must be vacated. Further vacating of people from spaces near the work area is recommended in the presence of infants (less than 12 months old), persons having undergone recent surgery, immune suppressed people, or people with chronic inflammatory lung diseases (e.g., asthma, hypersensitivity pneumonitis, and severe allergies). Containment may be limited or full, with negative air pressure and HEPA filtration exhausted outdoors. Containment may necessitate increased environmental monitoring to establish the effectiveness of containment. See Table 2 High: An indoor environment has been created in which immunosuppressed or allergic patients within the hospital are not fully protected against the risk of infection and the allergenic effects of exposure to environmental-source fungi and bacteria. (Pope, Patterson et al. 1993; Perdelli, Christina et al. 2006) The environmental conditions present a high risk for building occupants and intervention is necessary. The conditions exist for adverse health effects due to exposure to biological contaminants. Remediation is necessary, and during remediation, persons within the remediation area must be vacated. Vacating people from spaces adjacent to the work area is not necessary but is recommended in the presence of infants (less than 12 months old), persons having undergone recent surgery, immune suppressed people, or people with chronic inflammatory lung diseases (e.g., asthma, hypersensitivity pneumonitis, and severe allergies 
Assumptions and limitations of the determination of the exposure score
Assumptions
The following assumptions were made for the HRM: 1. Increasing surface area of microbial contamination represents an increased potential for exposure to fungal or bacterial environmental contaminants. 2. The maximum surface contamination score (from Tables 1-3) is utilized in determining the Health Risk Score as a marker of exposure. 3. The presence of an impeded exposure does not eliminate the risk associated with biological contamination within the hospital, and therefore, the EP was limited to reducing the exposure score by one-half (Table 4) . Environmental disturbances, routine maintenance, climate change, etc. can disturb bioaerosols that may be impeded and release them into the building. (Arnow, Andersen et al. 1978; Loo, Bertrand et al. 1996; Pegues, Daar et al. 2001; CDC 2003) Therefore, a residual risk of exposure remains, even if the exposure is considered impeded. 4. The risk levels are based on the input of experts in related fields to the hospital project.
The HRM does not set exposure limits but presents semi-quantitative risk levels based on exposure to microbiological contamination for the estimation of health risk in a hospital setting, where there is no doubt that persons who are ill will be present. There is also no doubt that microbial contamination is present indoors as confirmed by source sampling. See Assured report.
Limitations
The following limitations were identified when applying the HRM to the data: 1. The HRM may underestimate the health risk associated with small areas of growth or contamination in critical areas. For example, the investigators felt that the HR associated with a small amount microbial growth/contamination in a trauma room or surgical suite was significant and presented a high risk. The HRM, however could return a Health Risk Score falling in the low risk range for a small area of fungal growth or heavy contamination in a critical area. The HRM was designed to assess the risk of the entire facility in a broad sense and should not be utilized to assess risk based on one or a few samples. The samples should be of a sufficient number to characterize contaminated surfaces in the space under the control of each air handling unit. 2. The HRM is not sensitive to health risk associated with hidden microbial contamination, as invasive testing was not conducted. A large proportion of contaminated surfaces within buildings may remain hidden and are not visible without invasive investigation. (Dillon, Heinsohn et al. 1996 ) Therefore, the HRM may underestimate the health risk associated with hidden contamination. 3. The HRM may overestimate the health risk associated with large areas of contamination that are common to most buildings. Specifically, the investigators felt that the contamination identified in the return air ducts of the HVAC systems was unavoidable and not inconsistent with contamination that could be expected in a return air duct. The investigators felt that the contamination within return air ducts that did not have mold growth did not eliminate the risk associated with contamination, but was not represented by the HRM. Therefore, when calculating the ES for contamination within the return air ducts, the maximum square footage utilized in the calculations was 100 ft 2 . After reviewing the values of the HRM associated with the return air ducts, the investigators agreed that the Health Risk Score utilizing a maximum contamination surface area of 100 ft 2 adequately represented the health risk associated with contamination. 4. It is unlikely that adverse conditions and exposure to microbial contamination present within the hospital will affect building occupants equally and there are no exposure limits that would allow the calculation of an uncertainty rating to compare identified conditions with published exposure limits. Dose-response relationships are not available for comparison to environmental levels of indoor bioaerosols. There is no doubt, however that building occupants are being exposed to biological contaminants (allergens, opportunistic pathogens, and biological contaminants that can produce toxic metabolites) that have proliferated on indoor surfaces within the areas of the hospital investigated. The HRM prescribes semi-quantitative estimates of risk based on input from a multi-disciplinary team of professionals whose areas of specialization include microbial contamination in the indoor environment and indoor environmental control.
The HRM provides the hospital administration with a method to quantify the risk associated with indoor environmental contamination based on the conditions within the hospital. 5. The HRM does not consider additive or synergistic effects of exposure to multiple organisms and/or toxins/metabolites. 6. The HRM does not represent the indoor conditions of the facility during and immediately after maintenance activities, disruption in electrical service, or the start-up and shut down of the HVAC systems.
Conclusion
Allergic reactions to indoor allergens can produce inflammatory diseases of the eyes, nose, throat, and bronchi, which are medical problems that come under the headings of allergic conjunctivitis, allergic rhinitis, allergic asthma, and hypersensitivity pneumonitis (extrinsic allergic alveolitis) respectively. (Pope, Patterson et al. 1993 ) The Health Risk Model (HRM) considers the type of microbial contamination and the type of person expected to be within a specific Hospital location. Critical care areas are areas of the Hospital where it is expected that immunocompromised persons will be present and therefore contamination within a critical care area is given a higher weight in the overall determination of health risk. Risk assessment is a process designed to evaluate the potential relationship that may exist between exposure to aeroallergens and a particular effect (e.g. toxic effect, allergic sensitization, infection, allergic disease). (Pope, Patterson et al. 1993 ) A HRM was utilized to semi-quantitatively identify the health risk associated with fungal and bacterial surface contamination within the hospital. Monitoring for allergens can help characterize environments with respect to specific allergens (e.g., fungi and/or bacteria). Both fungi and bacteria secrete enzymes that act as allergens. (Pope, Patterson et al. 1993 Figure 9 below displays the HRM scores for the indoor space controlled by each AHU. (Venugopal, Venugopal et al. 1989; Trupl, Minarik et al. 1995; Huttova, Kralinsky et al. 1998; ) Basidiomycetes 1 (Bartz-Schmidt, Tintelnot et al. 1996; Nenoff, Horn et al. 1996; Rihs, Padhye et al. 1996; Nenoff, Friedrich et al. 1997; Sigler, Estrada et al. 1997; Verweij, van Kasteren et al. 1997 3-12, 16, 20, 28, 45-47] Akhunova and Shustova 1989; Akhunova 1991; Naidu 1993; Dhindsa, Naidu et al. 1995; Young, Hertl et al. 1995; Athar, Sekhon et al. 1996 Gonzalez, del Palacio et al. 1996; Muhm, Zuckermann et al. 1996; Linder, Keller et al. 1998; AerotechP&K 2006; Lai, Liaw et al. 2006 ) Rhodotorula species 1 (Walsh, Gonzalez et al. 1995; Huttova, Kralinsky et al. 1998; Costa, Marinho et al. 2000; Groll and Walsh 2001; Centeno and Machado 2004; AerotechP&K 2006 [3-6, 11, 34, 60, 65, 87-90 ] Scytalidium species 1 (Summerbell, Kane et al. 1989; Gaye, Samb et al. 1992 (Walsh, Gonzalez et al. 1995; Huttova, Kralinsky et al. 1998; Costa, Marinho et al. 2000; Groll and Walsh 2001; Centeno and Machado 2004; AerotechP&K 2006) Trichoderma species 1 1 1 (Guarro, Antolin-Ayala et al. 1999; Richter, Cormican et al. 1999; Walsh and Groll 1999; Fleming, Walsh et al. 2002; Myoken, Sugata et al. 2002; Kredics, Antal et al. 2003; De Miguel, Gomez et al. 2005 (Cheng, Horng et al. 2004) 1 (NNISR 1979; Poirier, Laurens et al. 1993; Davin-Regli, Bollet et al. 1998; Cheng, Horng et al. 2004) Bacillus species 1 (Richard, Van der Auwera et al. 1988; Matsumoto, Suenaga et al. 2000; Yang, Xu et al. 2000; Newman 2002) Bordetella bronchiseptica 1 1 (Bizet and Bizet 1995; StevensKrebbers, Schouten et al. 1999; Huebner, Christman et al. 2006) Burkholderia cepacia 1 1 (Jang, Kuo et al. 1999; Belchis, Simpson et al. 2000; Matrician, Ange et al. 2000; BureauChalot, Piednoir et al. 2003; Shehabi, Abu-Al-Soud et al. 2004; Balkhy, Cunningham et al. 2005; Berthelot, Grattard et al. 2005) www.intechopen.com 
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Burkholderia gladioli 1 1 (Wilsher, Kolbe et al. 1997; Otterbein, Splettstoesser et al. 1998; Clode, Metherell et al. 1999; Segonds, Heulin et al. 1999; Segonds and Chabanon 2001) Burkholderia species 1 1 (Otterbein, Splettstoesser et al. 1998; Segonds, Heulin et al. 1999; Segonds and Chabanon 2001) Chryseomonas luteola 1 (Hawkins, Moriarty et al. 1991; Ndugulile, Jureen et al. 2005) Citrobacter freundii 1 (Hodges, Degener et al. 1978; Tejada Artigas, Bello Dronda et al. 2001; Fiorio, Marroni et al. 2004; Ndugulile, Jureen et al. 2005 ) Comamonas acidovrans Diptheroids 1 (Schofferman, Zucherman et al. 1991) Enterobacter agglomerans 1 (Geere 1977; Goldmann, Dixon et al. 1978; Maki 1981; Astagneau, Gottot et al. 1994) Liu, Wong et al. 1999; Bellais, Girlich et al. 2002; Seetha, Bairy et al. 2002 ) Flavobacterium breve 1 1 (Bellais, Girlich et al. 2002) Gram (+) cocci 1 (Peter, Jehl et al. 1988; Rosina 1991; Zhang 1991; Pechere 1993; Astagneau 1998; Gayvallet-Montredon, Sauvestre et al. 1998; Raymond 2000) Gram (+) cocci in clumps 1 (Peter, Jehl et al. 1988; Rosina 1991; Zhang 1991; Pechere 1993; Astagneau 1998; Gayvallet-Montredon, Sauvestre et al. 1998; Raymond 2000) Gram (-) cocci 1 (Berk and Verghese 1989; Donowitz 1989; Zhang 1991 Micrococcus species 1 (Meyer, Eitzen et al. 1981; Hughes, Williams et al. 1986; Marinella, Pierson et al. 1997; Davies, Mehr et al. 2000 ) Myroides odoratum 1 1 (Mammeri, Bellais et al. 2002) Nocardia sp. 1 (Simpson, Stinson et al. 1981; Schaal and Lee 1992) Nocardioform 1 (Poonwan, Kusum et al. 1995; Votava, Skalka et al. 1997) Nocardioform bacilli 1 (Poonwan, Kusum et al. 1995; Votava, Skalka et al. 1997) Nocardioform bacilli Cog. 1 (Poonwan, Kusum et al. 1995; Votava, Skalka et al. 1997) Presumptive Nocardioform 1 (Poonwan, Kusum et al. 1995; Votava, Skalka et al. 1997) . 1982; Cohen 1986; Narayani, Naseema et al. 1990; Hell, Kern et al. 1999; Lang, Livesley et al. 1999; Szewczyk, Piotrowski et al. 2000; von Eiff, Proctor et al. 2001; von Eiff, Peters et al. 2002) Staphylococcus sciuri 1 (Lang, Livesley et al. 1999; Stepanovic, Dakic et al. 2002 The atmosphere may be our most precious resource. Accordingly, the balance between its use and protection is a high priority for our civilization. While many of us would consider air pollution to be an issue that the modern world has resolved to a greater extent, it still appears to have considerable influence on the global environment. In many countries with ambitious economic growth targets the acceptable levels of air pollution have been transgressed. Serious respiratory disease related problems have been identified with both indoor and outdoor pollution throughout the world. The 25 chapters of this book deal with several air pollution issues grouped into the following sections: a) air pollution chemistry; b) air pollutant emission control; c) radioactive pollution and d) indoor air quality.
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